Nemonapride
From Wikipedia, the free encyclopedia
| Systematic (IUPAC) name | |
|---|---|
|
N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide
|
|
| Clinical data | |
| Trade names | Emilace (JP) |
| AHFS/Drugs.com | International Drug Names |
| Legal status |
|
| Routes of administration |
Oral |
| Identifiers | |
| CAS Number | 75272-39-8 |
| ATC code | None |
| PubChem | CID 4452 |
| IUPHAR/BPS | 983 |
| UNII | Q88T5P3444 |
| KEGG | D01468 |
| Chemical data | |
| Formula | C21H26ClN3O2 |
| Molar mass | 387.90 g/mol |
|
|
| (verify) |
Nemonapride (エミレース, Emilace (JP)) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist. It has affinity for sigma receptors.
See also[edit]
References[edit]
| This article does not cite any sources. (November 2009) |
|
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |

